Evommune, Inc. (EVMN) Form 8-K — Nov 4, 2026
Evommune has licensed exclusive worldwide rights (excluding Greater China) to Hinova Pharmaceuticals' VAV1 degrader program, including molecular glue degrader EVO570, for all human and animal indications. Consideration includes a $20.0 million upfront cash payment, pre-funded warrants for 1.26 million shares worth $10.0 million, up to $150.0 million in development/regulatory milestones, and up to $920.0 million in commercial milestones plus tiered royalties. Alongside the license, Evommune priced a $30.0 million private placement of 4,966,889 shares at $6.04 per share, with Morgan Stanley and Leerink Partners acting as placement agents.
Key figures
- Gross Proceeds
- 30000000
- Offering Price
- 6.04
- Shares Offered
- 4966889
- Upfront Payment
- $20.0 million
- Cash runway
- into the second half of 2029
- Pro forma cash
- $292.3 million
- Warrant shares
- 1262413
- Warrant equity value
- $10.0 million
- Commercial milestones
- $920.0 million
- Warrant exercise price
- $0.001 per share
- Development regulatory milestones
- $150.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.